urothelial carcinoma (advanced) clinical trials results

atezolizumab versus chemotherapy
IMvigor211 (IC2/3),
NCT02302807
atezolizumab
versus
chemotherapy
patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimenopen label
global
atezolizumab versus nil
IMvigor210,
NCT02951767
Atezolizumab
versus
single arm study
Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. Cohort 2 will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen
durvalumab versus nil
durvalumab phase 1/2,
durvalumab at 10 mg/kg body weight administered as an intravenous infusion over 60 minutes every two weeks until disease progression or unacceptable toxicity
versus
patients with locally-advanced or metastatic urothelial carcinoma of the bladder who had progressed while on or after a platinum-containing chemotherapy, including those who progressed within 12 months of receiving therapy in a neoadjuvant or adjuvant setting
nivolumab versus nil
Checkmate 275,
NCT02387996
nivolumab 3 mg/kg intravenously every 2 weeks until disease progression and clinical deterioration, unacceptable toxicity, or other protocol-defined reasons
versus
patients with metastatic urothelial carcinoma after platinum therapy
pembrolizumab versus chemotherapy
KEYNOTE-045, 2017
NCT02256436
pembrolizumab
versus
investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine
patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapyopen-label